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a b s t r a c t
Aim of the study: To report a family with a novel TRIO gene mutation associated with
phenotype of cerebellar ataxia.
Materials and methods: Seven family members of Caribbean descent were recruited through
our ataxia research protocol; of the family members, the mother and all 3 children were
found to be affected with severe young-onset and rapidly progressive truncal and appen-
dicular ataxia leading to early disability. Array comparative genomic hybridization, mito-
chondrial DNA analysis, and whole-exome sequencing were performed on 3 of the family
members (mother and 2 daughters).
Results: While the maternal grandmother, great uncle and great aunt were unaffected, the
mother and 3 children displayed cognitive dysfunction, severe ataxia, spasticity, and speech
disturbances. Age of onset ranged between 3 and 17 years, with average current disease
duration of 21 years. Whole-exome sequencing showed a variant p.A1214V in exon 22 of the
TRIO gene in 3 of the family members. Array comparative genomic hybridization and
mitochondrial DNA analysis were normal. The same variant was later discovered in all
but one family member.
Conclusions and clinical implications: The TRIO p.A1214V variant is associated with cerebellar
ataxia in the studied family; it was present in all affected and unaffected family members.
Phenotype is severe and broad. Anticipation seems to be present (based on 2 affected
generations). It is warranted to screen additional familial early-onset and rapidly progres-
sive ataxia cases for this genotype. TRIO gene mutations may well represent a novel
spinocerebellar ataxia subtype.
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Spinocerebellar ataxia (SCA) is a formof autosomal-dominant
cerebellar ataxia involving the spinal cord and cerebellum
[1,2]. SCA occurs in 1 to 5 per 100,000 individuals worldwide
[3]. Over 40 genetic subtypes of SCA have been identiﬁed thus
far [1,2]. There is a clinical heterogeneity that accompanies
genetic heterogeneity [4,5]. The wide spectrum of phenotypic
manifestations in SCA subtypes include cognitive
deﬁcits; oculomotor disturbances; and neurologic dysfunc-
tion involving bulbar, cerebellar, extrapyramidal, and spinal
system impairment. Retinal abnormalities, intellectual dis-
ability (ID), and peripheral neuropathy have been associated
with genetic forms of cerebellar ataxia [1]. Oculomotor
disturbances, such as impaired pursuit and saccades and
nystagmus, have been documented in SCA patients [6,7].
Genetic studies have shown that certain classes of SCA are
caused by CAG or other trinucleotide repeat expansions,
while others are due to missense mutations and deletions
[1,2,4,8].1.1. Clinical rationale for the study
TRIO gene mutations have previously been correlated with ID
[9]. Gait ataxia was only detected in a single familial case
harboring a p.Asn1080lle variant on exon 19 of the TRIO gene
[10]. We describe a 3 generation family of Caribbean descent
presenting with ID, schizophrenia, behavioral symptoms,
speech disturbances, cerebellar ataxia, and spasticity carrying
a novel TRIO gene mutation.[(Fig._1)TD$FIG]
Fig. 1 – Family pedigree[22_TD$DIFF] drawn according to standard procedures
symbols indicate affected individuals. I-2, I-[24_TD$DIFF]3, II-2, and all memb
22 of the TRIO gene[2_TD$DIFF].2. Materials and methods
2.1. Standard protocol approval, patients consent, clinical
scales/assessments, sample collection
Our study was approved by the Institutional Review Board.
Seven family members (3 unaffected, 4 affected) were
recruited into the study (Fig. 1). Written informed consent
was obtained from all participants.
Neurologic evaluations included the Scale for Assessment
and Rating for Ataxia and Mini-Mental State Examination, in
addition to video recordings. We retrieved and reviewed all
available medical records dating back to childhood (over 20
years ago). Individuals III-1, III-2, and III-3 (discussed in more
detail below) were followed clinically by two of the co-authors
(Z.K.W. and R.J.U.), and ofﬁce visits/notes were reviewed.
2.2. Magnetic resonance imaging
Neuroradiologic imaging was obtained for members of the
third generation, and involvedMRI scans.We reviewed all MRI
sequences available that had been obtained for members of
the third generation for clinical purposes.
2.3. Genetic analysis
Whole-exome sequencing was performed on 4 family mem-
bers. Genomic DNA was extracted from blood and buccal
samples. DNA was sequenced using Illumina HighSeq system
with 100 bp paired-end reads, and mapped to the human
genome build GRCh37/UCSC hg19. The exonic regions and. Squares indicate men and circles, women. [23_TD$DIFF] ully darkened
ers of the[1_TD$DIFF] third [25_TD$DIFF]generation possess a p.Ala1214Val in exon
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GeneDx's XomeAnalyzer. Pathogenic variants were conﬁrmed
using capillary sequencing and other appropriate methods.
Human Genome Variation Society (HGVS) and International
System for Human Cytogenetic Nomenclature (ISCN) guide-
lines were utilized when stating the sequence and copy
number of variations.
In addition, the entiremitochondrial genomewas ampliﬁed
and sequenced via a solid state sequencing by-synthesis
process. DNA sequence was constructed and scrutinized in
comparison with the revised Cambridge Reference Sequence
(rCRS) and the reported variants and polymorphisms listed in
theMITOMAP database (http://mitomap.org). The presence of a
disease associated sequence variant, if present, was conﬁrmed
by conventional dideoxy sequence analysis or othermethods.A
reference library of more than 6000 samples from different
ethnic groups and online databases for mtDNA variations is
used to evaluate variants of unknown clinical signiﬁcance.
We tested for the presence of CAG trinucleotide expansion
in ATXN3 in patients and controls using Taq DNA Polymerase
and a primer set containing a FAM labeled primer. PCR
products were diluted, combined with GeneScan 500 LIZ dye
Size Standard and analyzed on the ABI 3730 Genetic Analyzer.
GeneMapper Software was used to size and genotype the
alleles.
The p.Ala1214Val mutation in the TRIO gene was ampliﬁed
fromgenomicDNA frompatients and controls usingAmpliTaq
Gold 360 (Thermo Fisher Scientiﬁc Inc.) in sequentially
nested polymerase chain reactions (PCRs). The following
primers were used: external primer pair 50-CTACCAT-
CAGCCGGTTTTCC-30 and 50-GGGCGTTAGGAAGAAGACC-30,
and internal primer pair 5-0CCGGTTTTCCTGTTCAGAGC-30
and 50-GTTTGCACAAGGCCATTTACCG-30. Samples from the
second PCR were run on a 2% NuSieve Agarose gel (Lonza,
Supplementary Fig. 1), puriﬁed and quantiﬁed. Approximately
50 ng of PCR product was used in a sequencing reaction
employing the BigDye Terminator v3.1 Cycle Sequencing Kit
(according to manufacturer's instructions, Applied Biosys-
tems) and 1 of the following sequencing primers: forward 50-
TTGAGGTTTCTGGCAGTCGG-30 or reverse 50-CGATTTGTTG-
GAATCTGAAG-30. Sequencing products were puriﬁed using
the Montage Seq96 Sequencing Reaction Cleanup Kit (accord-
ing to manufacturer's instructions, Millipore Sigma), and
analyzed on the Applied Biosystems ABI 3730 Genetic
Analyzer. The sequence was analyzed using Sequencher® [27_TD$DIFF]
version 4.8 DNA sequence analysis software (Gene Codes
Corporation).
2.4. Computational modeling
Computer-assistedmodelingwas completed using a sequence
of human triple functional domain protein (TRIO) taken from
the National Center for Biotechnology Information Reference
Accession Sequence, NP_009049 versionNP_009049.2, focusing
solely on domains 4, 5, and 6, and the inter-domain regions
spanning between Spectrin 3, Spectrin 4, and DH1 domains
(residues 878 through 1467), which forms a segment of 589
amino acids of the larger sequence.
Monte Carlo (MC) simulations were performed on the
altered proteins to observe local and regional changes for 589amino acids for the TRIO protein. A variant was modeled at p.
A1214V and subsequently compared to the wildtype.
YASARA is linux-based, modeling and simulation program
interface, which was utilized for biomolecular calculations for
the secondary-structure prediction (SSP) using a position-
speciﬁc scoring matrix (PSSM) from related sequences. Scan-
ning of depositories of PDBs for potential modeling templates,
which used with our programming codes forms composite
models for the full-sequence protein structure. Final molecular
reﬁnement for MC was built using the YASARA SSP/PSSM
method [11–16]. Relaxation of the structure was completed via
the YASARA/Amber force ﬁeld using YASARA knowledge-
based potentials utilizing YASARA's reﬁnement protocol [17],
we also allowed for the ﬁlling in of any gaps or unresolved
portions of both full-length protein structures beyondwhatwas
available in the crystallographic structure using ab initio
methods. Supplementary Fig. 2A shows the wildtype structure,
and Supplementary Fig. 2B shows the TRIO domain schematic.
Starting with the super positioning the YASARA-generated
initial model and mutant protein [11–13,15], then using the
Schrodinger's MC program (low modes type algorithm) coupled
with NAMD2 protocols was used to further reﬁne and generate
the ﬁnalized the models [13]. Review and development of the
overlapping regions yielded a complete protein model. Energy
optimization though a Polak–Ribière conjugate gradient with
an R-dependent dielectric was run on the ﬁnal model.
This conﬁrmation helped to verify correctness of chain
name, dihedrals, angles, torsions, non-bonds, electrostatics,
atom typing, and parameters using Maestro (Macromodel,
Schrodinger) and YASARA [18].
Conformational sampling was done through MC dynamics
searching (LCMOD-MC) [19–22]. Steepest descent or Polak–
Ribière conjugate gradient was used to minimize all systems;
and then the systems then proceeded to theMC search [19–22].3. Results
3.1. Clinical case descriptions
3.1.1. I-2 (63 years old)
I-2, the grandmother, is asymptomatic. TRIO gene p.A1214V
variant in exon 22 was apparent upon genetic analysis.
3.1.2. I-3 (62 years old)
I-3, the great-uncle, is asymptomatic. He was found to harbor
the same TRIO gene p.A1214V variant in exon 22 upon genetic
analysis.
3.1.3. I-4 (59 years old)
I-4, the great-aunt, is unaffected. She does not possess the
TRIO gene variant present in the other family members.
3.1.4. II-2 (44 years old)
II-2, themother, hadahistoryof seizures andbeganexperiencing
falls at 17 years of age. At 19, shewasdiagnosedwith postpartum
depression after her ﬁrst pregnancy. She progressively deterio-
rated cognitively, and physically was conﬁned to a wheel chair
following the birth of her third child. Upon evaluation, she had
right-sided torticollis with hypertrophy of the sternocleidomas-
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able to stand or move her legs. Severe spasticity with sustained
ankle clonus was present bilaterally; weakness in the lower
extremities was noted. She had dysmetria and dysdiadochoki-
nesia. Reﬂexes were exaggerated. No Babinski sign was present.
Superﬁcial sensation was normal. Speech was intelligible, one
word at a time. Shewas suffering fromdysphagia and bowel and
bladder incontinence.
3.1.5. III-1 (24 years old)
III-1, a woman with a past medical history of developmental
delay, schizophrenia, and depression, presented for an
evaluation of gait impairment. She was delivered at term
following an uncomplicated pregnancy. She began to display
muscle weakness and spasticity at age 9, attended regular
elementary school, and was enrolled in special education
during high school. Her loss of balance and falls began at 22
years of age; she has been ambulating with the assistance of a
walker since then and she requires assistance with most daily
activities. She had no history of seizures. She was diagnosed
with schizophreniform disorder with moderate ID after
neuropsychologic testing. It was also noted that she was
experiencing signs and symptoms of autistic spectrum
disorder; her cognitive screening score was in the very low
range. The patient has previously undergone commercial
genetic testing for SCA1, SCA2, SCA3, SCA5, SCA6, SCA7, SCA8,
SCA10, SCA12, SCA13, SCA14, SCA17, SCA18, Marinesco-
Sjogren syndrome (SIL1), Ataxia with isolated Vitamin E
deﬁciency (TTPA), Friedreich's Ataxia (FXN), Mitochondrial
recessive ataxia syndrome (MIRAS-POLG), Ataxia, early-onset,
with oculomotor apraxia and hypoalbuminemia (APTX), and
Senataxin (SETX). Array comparative genomic hybridization
and mitochondrial DNA analysis results were normal.
3.1.6. III-2 (22 years old)
III-2 has been struggling with ﬁne-motor coordination and
cognitive impairment since birth. She received speech therapy
during childhood, is independent in all daily living functions,
and has completed a 2-year training program as a patient care
technician. Her grandmother reported that the patient
experiences anger episodes; however, she does not display
signs of physical aggression during those episodes. She
sometimes displays obsessive compulsive behavior. The
patient reported that her balance has been impaired and
she has suffered near falls recently (over the past 3 months).
Her gait was spastic, speechwas ataxic, and lateral nystagmus
was present in both eyes. She had hyperactive deep tendon
reﬂexes in her lower extremities more so than in her upper
extremities, with sustained clonus present in her ankles.
Ataxia was present in all 4 extremities. She was able to regain
her balance with difﬁculty during a pull test. Her Mini-Mental
State Examination score was 27 out of 30 points. Patient's
psychological manifestations have increased in severity since
last follow up and will be undergoing neuropsychological
testing, she has also reported weakness and increase in
incoordination since last follow up.
3.1.7. III-3 (20 years old)
Cognitive and [29_TD$DIFF]learning delays began around 3–4 years of age in
III-3. He has struggled with clumsiness since childhood, andhis grandmother also noted ﬁne motor abnormalities. He had
been experiencing difﬁculty with speech, for which he
received therapy; upon presentation, his speech was dysarth-
ric in nature. In addition, he had experienced unprovoked
anger outbursts since age 17. Although present in all 4
extremities, ataxia was more pronounced in the lower
extremities and spasticity was more pronounced in the upper
extremities. On Mini-Mental State Examination, he scored 25
out of 30 points. It was determined that he has mild ID upon
neuropsychologic examination. He was found to harbor the
same variant in exon 22 of the TRIO gene as his grandmother,
great-uncle, mother, and 2 sisters. It has been noted that the
patient is experiencing more pronounced psychological
symptoms including anger outbursts since the last visit.
3.2. Magnetic resonance imaging
Loss of volume in the superior portion of the cerebellar vermis
was evident on MRI neuroradiologic imaging of patient III-1,
but brainstem atrophy was not apparent. Of note, the patient
also displayed mild bilateral parietal sulcal enlargement.
Patient III-2 displayed mild cerebellar vermian atrophy upon
imaging. Patient III-3 had a normal study (Fig. 2).
3.3. Genetic analysis
Array comparative genomic hybridization (aCGH), mitochon-
drial DNA (mtDNA) and whole exome sequencing were
performed on patients II-2, III-1, and III-2 prior to their
enrollment in the study. Results for aCGH and mtDNA were
normal. Whole-exome sequencing for the same family
members showed a variant (p.A1214V (GCG/GTG): c.3641
C > T) in exon 22 of the TRIO gene (NM_007118.2) and all
generations except I-4 were heterozygous for this variant on
chromosome 5 p15.2. The father of III-1, III-2, and III-3 was also
tested prior to enrollment, and he does not harbor this same
variant. The prevalence of this variant is 1:66,364, and occurs
at a rate of 0.0015% in alleles from individuals of European
(non-Finnish) descent, according to the ExAC dataset [23].
3.4. Computational modeling
TRIO forms internal domain interactions important to
function. The structural modeling drawn from radiographic
structural datasets demonstrated a strong effect from the
respective variants. The in silico results represent a comple-
mentary technique utilized to support the ﬁndings and
functions as a sorting tool to assist with variant classiﬁcation.
When compared towildtype, the stability of the object from
energetic calculations for DG per amino acid is higher for the
TRIO variant p.A1214V. Wildtype and p.A1214V were 224.62
and 638.35 kcal/mol Å2[28_TD$DIFF], respectively [19,20,22,24–27]. Per ami-
no acid, wildtype measured 0.382 kcal/mol Å2 and p.A1214V
1.084 kcal/mol Å2. Correspondingly, the p.A1214V protein
domains modeled (4–6) had worse total object stability when
not examined per amino acid distribution of energies.
The p.A1214V variant for the TRIO protein results in a large
conformational shift in the domain arrangement between
domains 5 (Spectrin 4) and 6 (DH1), likely altering protein
function due to location of inter-helical bundling within the
[(Fig._2)TD$FIG]
[3_TD$DIFF] ig. 2 – Sagittal cranial sections using MRI. (A) III-1 T1 sagittal flair; (B) III-2 T1 sagittal flair; and (C) III-3 sagittal SE T1 image.
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structural integrity. The actual residue mutation, p.A1214V,
induces a +0.408 kcal/mol Å2 change in free energy, which is
disruptive to the local region. Themolecular model for the full
structure and its variant form are displayed in Supplementary
Fig. 2 [19–22,27–34]. Local structural changes betweenwildtype
and p.A1214V is shown in Supplementary Fig. 2C and F.
Examination of the domain regions affected by the TRIO
variant consists of residues within the Spectrin 4 domain
(residues 1109–1216), and important domain-domain binding
sites are reduced or removed completely (residues C1041,
L1047, H1055, V1056, T1057, R1133, Q1136, C1137, Y1140, V1141,
E1144, Q1139, F1143, L1199, I1200, D1204, F1206, H1211, H1213,
I1217, K1218, K1219, and A1223) (Supplementary Fig. 2C–F). All
of the important domain contacts are lost over the duration of
simulation, allowing for the large rearrangement within
domain 4 and the spacer region adjacent, which has a
profound effect on the rest of the domains (domain 6 through
C-terminusdomain) (Supplementary Fig. 2A and E). This is also
pronounced in our electrostatic surface calculation for TRIO,
which shows how the helical bundling breaks down and an
extra lobe appears, which could frustrate partner protein
binding (Supplementary Fig. 3).
4. DiscussionTRIO is a diverse protein with many domains, including
guanine nucleotide exchange factor for RHOA and RAC1
GTPases [10,35]. TRIO is also utilized with the coordination
of actin remodeling, which is critically necessary for cell
migration and growth [36]. TRIO is found in developing
hippocampal neurons and can limit dendrite formation
without causing axon polarity. After dendrites are developed,
TRIO remains involved in synaptic function control via
regulation of the endocytosis of AMPA-selective glutamate
receptors at CA1 excitatory synapses.
Mutations involving the TRIO gene are associated with ID,
behavioral manifestations, and certain physical features, suchas microcephaly, as demonstrated by Ba et al. [9]. Our study
provides evidence that the TRIO gene p.A1214V variant in exon
22 is not only associated with ID and autism, it is also linked to
cerebellar ataxia. There is obvious heritability among the
family members in this pedigree (Fig. 1); the mutation is
transmitted in an autosomal dominant fashion among the
family members. The TRIO gene mutation is segregated in all
except one family member (I-4). Members of the second and
third generations share a similar phenotype. The age of onset
ranged from 3 to 17, with an average of 8.25 years. The TRIO
gene plays a role during neuronal development, assisting in
neurite outgrowth and basal synaptic transmission; thus, loss
of function inhibits both processes from taking place [35].
Seipel et al. [36] reported that the TRIO protein was associated
with cellular growth, migration, and spreading via orchestra-
tion of the function of the actin cytoskeleton. TRIO-deﬁcient
mice possess features of severe ataxia and multiple develop-
mental defects of the cerebellum [37], providing a plausible
explanation for the developmental delay and cognitive
impairment present in 4 of the family members in our study.
Cerebellar atrophy is evident upon imaging for the proband
(III-1) and her sister III-2 (Fig. 2). III-1 exhibits a considerable
amount of cerebellar vermian volume loss for her age, along
with an increase in the size of the 4th ventricle. Meanwhile
brainstem atrophy which is present in a number of spinocer-
ebellar ataxia patients is not apparent in III-1 and III-2. MRI for
III-3 was shown to be normal. Neuroradiology ﬁndings have
never been discussed in prior cases harboring TRIO gene
mutations, thus indicating that these ﬁndings prove to be novel.
Anticipation is demonstrated when symptoms occur at an
early age of onset and with higher level of severity than in the
previous generations [38]. It is evident in the family we studied.
While patients I-2, I-3 and I-4 remain unaffected, II-2 began to
present with symptoms at 17 years of age, and III-1 was 3 years
old at symptom onset. Early onset of symptoms and delay in
speechhavebeennotedamongotherpatientswith theTRIO gene
mutation [10], similar to all 3 siblings (III-1, III-2, and III-3), who
began speech therapy at or around 3 years of age. Psychiatric
manifestations are also present among family members of the
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postpartum depression following her ﬁrst pregnancy. At the age
of 22, patient III-1 developed signs and symptoms of schizophre-
nia. Patient III-2 currently encounters frequentmoodﬂuctuations
and often displays obsessive compulsive behavior, while patient
III-3 has anger outbursts that are medically managed. Psycho-
logical manifestations have worsened in two members of the
third generation since initial evaluation and III-2 is scheduled to
undergo neuropsychological testing upon the next visit. These
features ﬁt the phenotype described by Pengelly et al. [10]. The
same study reported one casewith gait ataxia. In this family all 4
affected individuals display clinical features of cerebellar ataxia.
Thus, we can safely infer that this TRIO genemutation is indeed
associated with ataxia.
Using established techniques, energetics-based andmodel-
ing examinations reveal conclusive defects in the p.A1214V
TRIO protein [19–22,24–27]. Models for the TRIO structure
reveal a striking loss of structural secondary and tertiary
contacts needed between the domains for proper enzymatic
function. The energetic calculations from measurements of
the TRIO structure show, in great detail, how the A1214V
variant (mutation) disrupts the wildtype protein in such a
manner that the variant protein would likely have a notable
disadvantage competing for binding partners compared to the
wildtype. A loss of function or a substantially decreased
amount of activity for the TRIO protein is expected given this
huge conformational change and breakdown between the
domain-domain interactions of the inter-protein sites, which
are critical for stability.
Similarly, energetic calculations frommeasurements of the
structure show greater instability for the variant than the
wildtype protein. Losing the domain interactions could
account for loss of or a considerable decrease in function for
this protein. The structural model of this variant concurs with
the clinical data. Protein modeling can be precisely employed
as a useful tool for the arduous task of variant categorization.
Further studies of including participants with similar pheno-
type and mutation are warranted in order to solidify the
involvement of cerebellar ataxia among patients with TRIO
gene mutations.
5. Clinical implications/future directionsThe TRIO p.A1214[30_TD$DIFF]V variant is associated with cerebellar ataxia
in the family we studied; it was present in all affected family
members and [31_TD$DIFF]two unaffected members. The phenotype is
severe and broad. Anticipation seems to be present (based on 2
affected generations). Screening of more familial early-onset
and rapidly progressive ataxia cases for this genotype is
warranted. The TRIO gene mutations may well represent a
novel SCA subtype.
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